Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
8,187
datasets available to search
ShareScore release 0.7.1
Dataset results
8,187 results for “Lung cancer”
Genomic features of lung cancer patients in Indonesia’s National Cancer Center
Open the record for dataset details and reuse information.
Data from: Early treatment response in non-small cell lung cancer patients using diffusion-weighted imaging and functional diffusion maps - a feasibility study
Open the record for dataset details and reuse information.
Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade
Open the record for dataset details and reuse information.
Data from: Epigenomic study identifies a novel mesenchyme homeobox2-GLI1 transcription axis involved in cancer drug resistance, overall survival and therapy prognosis in lung cancer patients
Open the record for dataset details and reuse information.
A Tasquinomod-loaded dopamine-modified pH sensitive hydrogel is effective at inhibiting the proliferation of KRAS mutant lung cancer cells
Open the record for dataset details and reuse information.
CarcSeq measurement of lung cancer driver mutations predicts mouse strain- and sex-related incidence of spontaneous lung neoplasia
Open the record for dataset details and reuse information.
Dataset related to article "The Atypical Receptor CCRL2 Is Essential for Lung Cancer Immune Surveillance."
<p>CCRL2 is a nonsignaling seven-transmembrane domain receptor. CCRL2 binds chemerin, a protein that promotes chemotaxis of leukocytes, including macrophages and natural killer (NK) cells. In addition, CCRL2 controls the inflammatory response in different pathologic settings, such as hypersensitivity, inflammatory arthritis, and experimental autoimmune encephalitis. Here, we investigated the role of CCRL2 in the regulation of lung cancer-related inflammation. The genetic deletion of <em>Ccrl2</em> promoted tumor progression in urethane-induced and in <em>Kras</em> <sup>G12D/+</sup>/<em>p53</em> <sup>LoxP</sup> lung tumor mouse models. Similarly, a <em>Kras</em>-mutant lung tumor displayed enhanced growth in <em>Ccrl2</em>-deficient mice. This phenotype was associated with a reduced inflammatory infiltrate characterized by the impaired recruitment of several leukocyte populations including NK cells. Bone marrow chimeras showed that CCRL2 expression by the nonhematopoietic cell compartment was responsible for the increased tumor formation observed in <em>Kras</em>-mutant <em>Ccrl2</em>-deficient mice. In human and mouse lungs, CCRL2 was expressed by a fraction of CD31<sup>+</sup> endothelial cells, where it could control NK infiltration. Elevated CCRL2 expression in biopsies from human lung adenocarcinoma positively correlated with clinical outcome. These results provide evidence for a crucial role of CCRL2 in shaping an anti-lung tumor immune response.</p>
Dynamical network analysis reveals key microRNAs in progressive stages of lung cancer
<p>This repository contains clinical data of LUAD samples (phnotype.csv; TCGA-LUAD.survival.tsv), microRNA targets data of RNAs-RNAs relationships (mirna-lnc.txt; mirna-mrna.csv), and RNAs expression data of LUAD (ENSG_ID.txt; ENSG_ID_LNC.txt; idMap.data; TCGA-LUAD.htseq_fpkm.tsv; TCGA-LUAD.mirna.tsv) used in <em>Dynamical network analysis reveals key microRNAs in progressive stages of lung cancer</em>.</p> <p> </p>
Trust and Acceptance of Lung Cancer Screening Strategies Questionnaire and Data
<p>Lung cancer is one of the deadliest cancers today. Despite the widespread knowledge that early detection is crucial for cancer treatment, the majority of patients are diagnosed in an advanced stage with a significantly shorter 5-year survival rate. Lung cancer screening allows for early detection of cancer before symptoms arise. Currently, there are plans to introduce a lung cancer screening program in the Netherlands. The goal of this study is to gain knowledge about the effect of an individual's degree of trust on the acceptance level for different Lung Cancer Screening Strategies among people living in the Netherlands. This knowledge helps healthcare providers and professionals as well as the developers of screening software. Also, it supports the development of the best possible patient experience in the future. This survey consists of 30<strong> </strong>questions and should not take longer than 10 minutes to complete.</p>
Metabolomics dataset for identification of metabolites associated with survival in lung cancer patients under treatment
<p>Non small cell lung cancer patients' serum samples were collected before treatment. The samples were analyzed by metabolomics using high resolution NMR and untargeted lipidomics using high resolution UPLC-MS. The data was used to identify the predictors of overall survival in the patients after they underwent treatment.</p>
Metabolic syndrome and risk of lung cancer: An analysis of Korean National Health Insurance Corporation database
<p>Introduction: Metabolic syndrome is known to increase the risk of several cancers. However, the association between lung cancer and metabolic syndrome remains unclear. Thus, we investigated the impact of metabolic syndrome on the incidence of lung cancer.</p> <p>Methods: This study enrolled participants in a health screening program provided by the Korean National Health Insurance Service between January 2009 and December 2012. The incidence of lung cancer was observed until December 2016. We analyzed the risk of lung cancer according to the presence of metabolic syndrome, metabolic syndrome components, and number of metabolic syndrome components.</p> <p>Results: During the study, 45,635 new cases of lung cancer were recorded among 9,586,753 participants. The presence of metabolic syndrome and all its components was positively associated with the risk of lung cancer in males after multivariate adjustment (hazard ratio (HR) of metabolic syndrome 1.15, 95% confidence interval (CI) = 1.12–1.18). The risk of lung cancer increased with the number of components present. The effect of metabolic syndrome on the increasing risk of lung cancer is may be higher in underweight male ever smokers than in other participants.</p> <p>Conclusion: Metabolic syndrome was associated with an increased risk of lung cancer in males. Moreover, the higher the number of metabolic syndrome components, the higher the risk of lung cancer.</p>
Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: A systematic review
<p><b>Objectives:</b> Use of immune checkpoint inhibitors (ICIs) as first-line treatment for advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) remains controversial. Clinical trials comparing single-drug immunotherapy (IO) with immunotherapy plus chemotherapy (IC) are lacking. We aimed to compare the efficacy of IO alone with that of IC as first-line treatment for advanced NSCLC.</p> <p><b>Design: </b>Systematic review</p> <p><b>Data sources: </b>PubMed, the Cochrane Library, and Embase for related studies on NSCLC; ClinicalTrials.gov, American Society of Clinical Oncology Meeting Library, and World Conference on Lung Cancer for relevant conference abstracts.</p> <p><b>Eligibility criteria: </b>Articles<b> </b>meeting the following<b> </b>criteria were selected: (1) randomized controlled trials on NSCLC treatment, (2) all individuals in the studies had not received treatment previously, and (3) research on IO monotherapy using programmed death-1/programmed death ligand-1 (PD-L1) inhibitors or IC.</p> <p><b>Data extraction and synthesis:</b> After reading the original literature, two reviewers independently extracted the relevant information. The primary outcomes were progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). We also extracted data on treatment-related adverse events and immune-related adverse events (irAEs).</p> <p><b>Results:</b> Overall, 10 randomized controlled clinical trials (n = 5765) were included. As first-line treatment for advanced NSCLC, IC tended to yield better PFS, OS, and ORR than did IO. Furthermore, IC yielded significantly better PFS than IO when tumor PD-L1 expression was at least 50% (HR: 1.81, 95% CI: 1.18–2.78) and yielded a better OS and PFS when tumor PD-L1 expression was at least 1%; IO resulted in fewer adverse events than did IC. However, the incidence of irAEs was higher for IO than for IC.</p> <p><b>Conclusions:</b> The findings of the indirect comparison indicate that IC as first-line treatment for advanced NSCLC is significantly more effective than IO in patients with PD-L1 expression in at least 50% of tumor cells.</p>
Data from: Exogenous restoration of TUSC2 expression induces responsiveness to erlotinib in wildtype epidermal growth factor receptor (EGFR) lung cancer cells through context specific pathways resulting in enhanced therapeutic efficacy
Expression of the tumor suppressor gene TUSC2 is reduced or absent in most lung cancers and is associated with worse overall survival. In this study, we restored TUSC2 gene expression in several wild type EGFR non-small cell lung cancer (NSCLC) cell lines resistant to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib and analyzed their sensitivity to erlotinib in vitro and in vivo. A significant inhibition of cell growth and colony formation was observed with TUSC2 transient and stable expression. TUSC2-erlotinib cooperativity in vitro could be reproduced in vivo in subcutaneous tumor growth and lung metastasis formation lung cancer xenograft mouse models. Combination treatment with intravenous TUSC2 nanovesicles and erlotinib synergistically inhibited tumor growth and metastasis, and increased apoptotic activity. High-throughput qRT-PCR array analysis enabling multi-parallel expression profile analysis of eighty six receptor and non-receptor tyrosine kinase genes revealed a significant decrease of FGFR2 expression level, suggesting a potential role of FGFR2 in TUSC2-enhanced sensitivity to erlotinib. Western blots showed inhibition of FGFR2 by TUSC2 transient transfection, and marked increase of PARP, an apoptotic marker, cleavage level after TUSC2-erlotinb combined treatment. Suppression of FGFR2 by AZD4547 or gene knockdown enhanced sensitivity to erlotinib in some but not all tested cell lines. TUSC2 inhibits mTOR activation and the latter cell lines were responsive to the mTOR inhibitor rapamycin combined with erlotinib. These results suggest that TUSC2 restoration in wild type EGFR NSCLC may overcome erlotinib resistance, and identify FGFR2 and mTOR as critical regulators of this activity in varying cellular contexts. The therapeutic activity of TUSC2 could extend the use of erlotinib to lung cancer patients with wildtype EGFR.
Data from: How do organisational characteristics influence teamwork and service delivery in lung cancer diagnostic assessment programmes? A mixed-methods study
Objectives: Diagnostic assessment programs (DAPs) can reduce wait times for cancer diagnosis but optimal DAP design is unknown. This study explored how organizational characteristics influenced multidisciplinary teamwork and diagnostic service delivery in lung cancer DAPs. Design: A mixed methods approach integrated data from descriptive qualitative interviews and medical record abstraction at four lung cancer DAPs. Findings were analyzed with the Integrated Team Effectiveness Model. Setting: Four DAPs at two teaching and two community hospitals in Canada Participants: Twenty-two staff were interviewed about organizational characteristics, target service benchmarks, and teamwork processes, determinants and outcomes; 314 medical records were reviewed for actual service benchmarks. Results: Formal, informal and asynchronous team processes enabled service delivery and yielded many perceived benefits at the patient, staff and service levels. However, several DAP characteristics challenged teamwork and service delivery: referral volume/workload, time since launch, days per week of operation, rural-remote population, number and type of full-time/part-time human resources, staff co-location, information systems. As a result, all sites failed to meet target benchmarks (from referral to consultation median 4.0 visits, median wait time 35.0 days). Recommendations included improved information systems, more staff in all specialties, staff co-location and expanded roles for patient navigators. Findings were captured in a conceptual framework of lung cancer DAP teamwork determinants and outcomes. Conclusions: This study identified several DAP characteristics that could be improved to facilitate teamwork and enhance service delivery, thereby contributing to knowledge of organizational determinants of teamwork and associated outcomes. Findings can be used to update existing DAP guidelines, and by managers to plan or evaluate lung cancer DAPs. Ongoing research is needed to identify ideal roles for navigators, and staffing models tailored to case volumes.
Data from: Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
Objectives: Bevacizumab and erlotinib inhibit different tumour growth pathways, and both exhibit beneficial effects in the treatment of non-small-cell lung cancer (NSCLC). However, the efficacy of bevacizumab in combination with erlotinib remains controversial. Therefore, we conducted a meta-analysis to compare combination treatment with bevacizumab and erlotinib to bevacizumab or erlotinib monotherapy in the treatment of NSCLC. Methods: Randomised controlled trials (RCTs) published in PubMed, Web of Science and EMBASE were systematically reviewed. The main outcome measures included overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and adverse events. Results were expressed as HRs or risk ratios (RRs) with 95% CIs. Results: 5 RCTs involving a total of 1736 patients were included in this meta-analysis. The combination of bevacizumab and erlotinib significantly improved PFS (HR=0.63, 95% CI 0.53 to 0.75; p=0.000) and the ORR (RR=1.91, 95% CI 1.19 to 3.06; p=0.007) in the second-line treatment of NSCLC compared with bevacizumab or erlotinib alone. However, no significant difference in OS was observed between the combination and monotherapy groups (HR=0.96, 95% CI 0.83 to 1.11; p=0.573). A subgroup analysis has shown that the greatest PFS benefit was associated with an age of <65 years(HR=0.74, 95% CI 0.57 to 0.96; p=0.026), Asian/Pacific Islander ethnicity (HR=0.23, 95% CI 0.10 to 0.54; p=0.001), Eastern Cooperative Oncology Group performance status (ECOG PS) 1 (HR=0.82, 95% CI 0.68 to 0.98; p=0.033), stage IIIB or IV disease (HR=0.68, 95% CI 0.57 to 0.82; p=0.000) and no history of smoking (HR=0.48, 95% CI 0.32 to 0.71; p=0.000). The incidence of grade 3/4 adverse events such as rash and diarrhoea was higher in the combination group than in the monotherapy group. Conclusions: The addition of bevacizumab to erlotinib can significantly improve PFS and the ORR in the second-line treatment of NSCLC with an acceptable and manageable risk of rash and diarrhoea. Further well-conducted, large-scale trials are needed to validate these findings.
Pathological images of non-small cell lung cancer
<p>The dataset comprises lung cancer patient information and pathology images utilized for the analysis of our study. These are anonymized data from cases in our cohort for which patient consent was obtained for public deposition. </p> <p>Patient information for original cohort and validation cohort is described in the Excle files, "original_cohort_patient_info.xlsx" and "validation_cohort_patient_info.xlsx", respectively. </p> <p>These Excel files contain information on sex, age, smoking history, pathological stage, histology, lymphovascular invasion, pleural invasion, lymph node metastasis, adjuvant treatment, survival outcomes and file names for pathological images of each patient. Each patient has two files of Whole Slide Images files (format: .npdi) including hematoxylin & eosin staining ("XXX_h.ndpi") and immunohistochemistry stainig for PD-L1 ("XXX_p.ndpi").</p>
Integration of Single-Cell Analysis and Mendelian Randomization Reveals NET1 as a Potential Key Player in Lung Cancer Pathogenesis
Open the record for dataset details and reuse information.
Figure 1 from: Zlatanova T, Arabadjiev J (2024) The prognostic role of markers of systemic inflammation in patients with metastatic lung cancer receiving immunotherapy: A comprehensive review of the literature. Pharmacia 71: 1-7. https://doi.org/10.3897/pharmacia.71.e115558
Figure 1 Biological Hallmarks of Cancer, Source: Adapted from Hallmarks of Cancer: The Next Generation, Hanahan D., Weinberg R.A. , Cell, Volume 144, ISSUE 5, P646-674, March 04, 2011, https://doi.org/10.1016/j.cell.2011.02.013.
NLSTseg: A Pixel-level Lung Cancer Dataset Based on NLST LDCT Images
Open the record for dataset details and reuse information.
Data from: Downregulation of circATXN7 represses non-small cell lung cancer growth by releasing miR-7-5p
<p>Circular RNAs (circRNAs) participate in the occurrence and progression of many cancers. CircRNA ataxin 7 (circATXN7) (circBase ID: hsa_circ_0066436) plays a promoting influence on gastric cancer progression. However, the biological role of circATXN7 in non-small cell lung cancer (NSCLC) is indistinct. CircATXN7 and PFN2 were highly expressed in NSCLC, whereas miR-7-5p expression had the opposite trend. CircATXN7 overexpression constrained apoptosis and promoted proliferation, metastasis, invasion, and epithelial-mesenchymal transition (EMT) of NSCLC cells, but circATXN7 silencing played the opposing influence and repressed xenograft tumor growth <i>in vivo</i>. CircATXN7 served as a miR-7-5p sponge, and circATXN7 regulated malignant behaviors of NSCLC cells through sponging miR-7-5p. PFN2 acted as a miR-7-5p target. PFN2 silencing overturned the promoting effect of miR-7-5p inhibitor on NSCLC cell malignancy, while PFN2 overexpression reversed the inhibitory impact of miR-7-5p mimic on NSCLC cell malignancy. CircATXN7 accelerated the malignancy of NSCLC cells through adsorbing miR-7-5p and upregulating PFN2, offering evidence to support circATXN7 as a might target for NSCLC treatment.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.